Effect of a short-term diet and exercise intervention on inflammatory/antiinflammatory properties of HDL in overweight/obese men with cardiovascular risk factors

Journal of Applied Physiology

Volumn 101, Issue 6, 2006, Pages 1727-1732

  Roberts, Christian K ^a   Ng, Carey ^a   Hama, Susan ^a   Eliseo, Anna Jane ^a   Barnard, R James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; High density lipoprotein; Lipids; Paraoxonase; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXONASE 3; TRIACYLGLYCEROL;

ADULT; AEROBIC EXERCISE; AGED; ANTHROPOMETRY; ARTERY WALL; ARTICLE; CARDIOVASCULAR RISK; CHEMOTAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COCULTURE; CONTROLLED STUDY; DIET THERAPY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIGH FIBER DIET; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; LOW FAT DIET; MALE; METABOLIC SYNDROME X; MONOCYTE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SHORT COURSE THERAPY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CORONARY ARTERIOSCLEROSIS; DIET THERAPY; EXERCISE THERAPY; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33845448954     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00345.2006     Document Type: Article

References (46)

1. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, and Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751-2756, 2003.
2. Assmann G, Schulte H, von Eckardstein A, and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124: S11-S20, 1996.
3. Auerbach BJ, Kiely JS, and Cornicelli JA. A spectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. Anal Biochem 201: 375-380, 1992.
4. Barnard RJ. Effects of life-style modification on serum lipids. Arch Intern Med 151: 1389-1394, 1991.
5. Barnard RJ and Inkeles SB. Effects of an intensive diet and exercise program on lipids in postmenopausal women. Womens Health Issues 9: 155-161, 1999.
6. Brinton EA, Eisenberg S, and Breslow JL. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest 85: 144-151, 1990.
7. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, and Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838, 1986.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, and Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622, 1998.
9. Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285: 2486-2497, 2001.
10. Fogelman A, Elahi F, Sykes K, Van Lenten B, Territo M, and Berliner J. Modification of the Recalde method for the isolation of human monocytes. J Lipid Res 29: 1243-1247, 1988.
11. Fogelman AM. When good cholesterol goes bad. Nat Med 10: 902-903, 2004.
12. Franceschini G, Sirtori CR, Capurso A 2nd, Weisgraber KH, and Mahley RW. AIMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 66: 892-900, 1980.
13. Friedewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
14. Gan KN, Smolen A, Eckerson HW, and La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100-106, 1991.
15. Gordon T, Castelli WP, Hjortland MC, Kannel WB, and Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714, 1977.
16. Keys A. Seven Countries: A Mulitvariate Analysis of Death and Coronary Heart Disease. Cambridge, MA: Harvard University Press, 1980.
17. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, and Mutanen M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 160: 425-432, 2002.
18. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, and Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002.
19. Lichtenstein AH and Van Horn L. Very low fat diets. Circulation 98: 935-939, 1998. [Corrigenda. Circulation 98 October 1998, p. 1828.]
20. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, and Fogelman AM. The double jeopardy of HDL. Ann Med 37: 173-178, 2005.
21. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, and Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41: 1495-1508, 2000.
22. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, and Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41: 1481-1494, 2000.
23. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, and Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42: 1308-1317, 2001.
24. Navab M, Hama SY, Ready ST, Ng CJ, Van Lenten BJ, Laks H, and Fogelman AM. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 13: 363-372, 2002.
25. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88: 2039-2046, 1991.
26. Navab M, Van Lenten BJ, Reddy ST, and Fogelman AM. High-density lipoprotein and the dynamics of atherosclerotic lesions. Circulation 104: 2386-2387, 2001.
27. Nicholls SJ, Zheng L, and Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 15: 212-219, 2005.
28. Ninio E. Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care 8: 123-131, 2005.
29. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, and Robins SJ. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556-1563, 2006.
30. Reddy S, Hama S, Grijalva V, Hassan K, Mottahedeh R, Hough G, Wadleigh DJ, Navab M, and Fogelman AM. Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells. J Biol Chem 276: 17030-17035, 2001.
31. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, and Fogelman AM. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21: 542-547, 2001.
32. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 105: 2-4, 2002.
33. Roberts CK, Vaziri ND, and Barnard RJ. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation 106: 2530-2532, 2002.
34. Roberts CK, Won D, Pruthi S, Kurtovic S, Sindhu RK, Vaziri ND, and Barnard RJ. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 100: 1657-1665, 2006.
35. Stafforini DM, McIntyre TM, and Prescott SM. Platelet-activating factor acetylhydrolase from human plasma. Methods Enzymol 187: 344-357, 1990.
36. Stafforini DM, McIntyre TM, Zimmerman GA, and Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 272: 17895-17898, 1997.
37. Stamler J, Wentworth D, and Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823-2828, 1986.
38. Stremler KE, Stafforini DM, Prescott SM, and McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 266: 11095-11103, 1991.
39. Thompson D, Basu-Modak S, Gordon M, Poore S, Markovitch D, and Tyrrell RM. Exercise-induced expression of heme oxygenase-1 in human lymphocytes. Free Radic Res 39: 63-69, 2005.
40. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, and Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96: 2758-2767, 1995.
41. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, and Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103: 2283-2288, 2001.
42. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, and Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 2882-2891, 1995.
43. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, and Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95: 774-782, 1995.
44. Wegge JK, Roberts CK, Ngo TH, and Barnard RJ. Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. Metabolism 53: 377-381, 2004.
45. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, and Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111: 980-987, 2005.
46. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, and Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529-541, 2004.